APA

De Divitiis C., von Arx C., Grimaldi A. M., Cicala D., Tatangelo F., Arcella A., Romano G. M., Simeone E., Iaffaioli R. V., Ascierto P. A. & Tafuto S. (20171016). Metronomic temozolomide as second line treatment for metastatic poorly differentiated pancreatic neuroendocrine carcinoma. : Journal of translational medicine.

Chicago

De Divitiis C, von Arx C, Grimaldi A M, Cicala D, Tatangelo F, Arcella A, Romano G M, Simeone E, Iaffaioli R V, Ascierto P A and Tafuto S. 20171016. Metronomic temozolomide as second line treatment for metastatic poorly differentiated pancreatic neuroendocrine carcinoma. : Journal of translational medicine.

Harvard

De Divitiis C., von Arx C., Grimaldi A. M., Cicala D., Tatangelo F., Arcella A., Romano G. M., Simeone E., Iaffaioli R. V., Ascierto P. A. and Tafuto S. (20171016). Metronomic temozolomide as second line treatment for metastatic poorly differentiated pancreatic neuroendocrine carcinoma. : Journal of translational medicine.

MLA

De Divitiis C, von Arx C, Grimaldi A M, Cicala D, Tatangelo F, Arcella A, Romano G M, Simeone E, Iaffaioli R V, Ascierto P A and Tafuto S. Metronomic temozolomide as second line treatment for metastatic poorly differentiated pancreatic neuroendocrine carcinoma. : Journal of translational medicine. 20171016.